1332.HK falls 62.96% to HK$0.10 on 23 Jan 2026: assess liquidity pressures
1332.HK stock opened the session after a sharp sell-off and closed the Hong Kong market at HK$0.10, down 62.96% on 23 Jan 2026. The share rout came with a flood of volume at 533,662,844 shares versus an average of 5,119,456, marking Touyun Biotech Group Limited (1332.HK) among the day’s most active HKSE names. Traders should note the gap from the 50-day average price HK$0.27 and the company’s weak liquidity metrics. We break down what moved the price, where support may lie, and what our models and grade say about risk and potential reward.
1332.HK stock market snapshot
Touyun Biotech Group Limited (1332.HK) closed on the HKSE at HK$0.10 on 23 Jan 2026, after trading between HK$0.09 and HK$0.26. The intraday drop was 62.96%, with market cap at about HK$729,453,920 and year range HK$0.07–HK$0.75. Volume spiked to 533,662,844, far above the average of 5,119,456, making it one of Hong Kong’s most active issues today.
Why Touyun Biotech (1332.HK) moved today
The sharp fall and outsized volume point to large-scale selling rather than routine profit-taking. Today’s volume — roughly 104× the average — suggests block trades, forced liquidation, or stop-loss clustering. There is no single confirmed public announcement from the company linked to this move at time of writing; investors should check filings and the company site for updates source.
Fundamentals and valuation look strained
Touyun’s trailing EPS is -0.01 and the reported PE is -26.00, reflecting losses. Key balance metrics show pressure: current ratio 0.20, negative shareholders equity per share, and working capital shortfall of HK$492,672,000. Price sits below the 50-day average (HK$0.27) but above the year low (HK$0.07).
Meyka AI rates 1332.HK with a score out of 100
Meyka AI rates 1332.HK with a score out of 100: 60.17 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade highlights mixed signals: diversified business segments but weak liquidity and negative margins. These grades are not guaranteed and do not constitute financial advice.
Technical read: volatility, momentum and support levels
Momentum indicators are bearish but oversold: RSI 39.52, CCI -129.98, Williams %R -90.36. Bollinger bands show a widened range (middle HK$0.24, upper HK$0.27, lower HK$0.20) with ATR HK$0.03, indicating elevated volatility. Short-term resistance is near the 50-day average HK$0.27; key support sits toward the year low HK$0.07. Traders should treat intraday rebounds cautiously given thin effective liquidity at extreme price levels.
Meyka AI’s forecast model projects near-term levels and price targets
Meyka AI’s forecast model projects a monthly level of HK$0.23, a quarterly target of HK$0.27, and a one-year projection around HK$0.13. Versus the close at HK$0.10, that implies model-based upside of roughly +130.00% (monthly), +170.00% (quarterly), and +25.00% (one year). Forecasts are model-based projections and not guarantees. For conservative planning we suggest a base case price target of HK$0.15 and a bear case of HK$0.05, reflecting liquidity and solvency risks on the HKSE in Hong Kong.
Final Thoughts
1332.HK stock closed the Hong Kong session at HK$0.10 on 23 Jan 2026 after a volume-driven crash that put the name among the market’s most active issues. Fundamentals show negative trailing EPS and strained liquidity (current ratio 0.20, working capital deficit HK$492,672,000), which helps explain heightened sensitivity to large orders. Meyka AI’s forecast model projects a quarterly target near HK$0.27, implying substantial upside versus today’s price, but that view sits against operational and balance-sheet risks. Our Meyka grade (score 60.17, Grade B, HOLD) reflects this tension: diversified revenue streams and pockets of growth, countered by weak cash conversion and negative equity. Short-term traders should prioritise liquidity and stop management; longer-term investors should await clearer evidence of margin recovery and improved current liquidity. Remember, model forecasts and grades are projections and not guarantees; monitor company filings and HKSE disclosures, and use position sizing to limit downside on this highly volatile Hong Kong-listed stock.
FAQs
What drove the 62.96% drop in 1332.HK stock on 23 Jan 2026?
The move was driven by extraordinary volume 533,662,844 versus average 5,119,456, suggesting block selling or forced liquidations. No single public corporate announcement explained it at publication; check company filings and the Touyun Biotech site for updates.
How does Meyka AI view 1332.HK stock now?
Meyka AI rates 1332.HK at 60.17 (Grade B, HOLD). The score balances diversified business lines against weak liquidity and negative margins. This is informational and not investment advice.
What are realistic price targets for 1332.HK stock?
Meyka AI’s model projects HK$0.23 (monthly) and HK$0.27 (quarterly); a conservative base case price target is HK$0.15 and a bear case HK$0.05. Forecasts are model projections, not guarantees.
What risks should investors note for 1332.HK stock?
Key risks include low current ratio 0.20, negative shareholders equity, long receivable days (DSO 200), and volatile liquidity on the HKSE. These issues can amplify price moves in either direction.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
